Afya (NASDAQ:AFYA – Get Free Report) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Monday, Wall Street Zen reports.
Several other research analysts have also commented on AFYA. Morgan Stanley upgraded shares of Afya from an “underweight” rating to an “equal weight” rating and set a $12.60 price target on the stock in a research note on Thursday, November 5th. Bradesco Corretora raised shares of Afya to an “outperform” rating and set a $17.00 price objective for the company in a research note on Thursday, September 24th. Citigroup raised shares of Afya from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $16.00 to $12.00 in a research note on Tuesday, November 3rd. Weiss Ratings cut shares of Afya from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, October 29th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Afya from $19.00 to $17.50 and set an “overweight” rating on the stock in a research report on Tuesday, November 3rd. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.18.
Get Our Latest Analysis on AFYA
Afya Price Performance
Shares of AFYA opened at $10.30 on Monday. The firm has a market cap of $965.32 million, a PE ratio of 5.67, a PEG ratio of 1.62 and a beta of 0.43. The firm’s 50 day moving average price is $12.65 and its 200 day moving average price is $13.95. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.08 and a current ratio of 2.08. Afya has a twelve month low of $9.66 and a twelve month high of $16.16.
Insider Buying and Selling at Afya
In other news, insider Santos Welder Ferreira sold 4,161 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $13.30, for a total value of $55,341.30. Following the sale, the insider owned 35,000 shares in the company, valued at approximately $465,500. This trade represents a 10.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Hedge Funds Weigh In On Afya
Several large investors have recently bought and sold shares of AFYA. Goldman Sachs Group Inc. bought a new position in shares of Afya during the 3rd quarter worth about $1,043,000. Dodge & Cox raised its position in shares of Afya by 33.5% during the third quarter. Dodge & Cox now owns 68,487 shares of the company’s stock valued at $825,000 after buying an additional 17,200 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of Afya during the third quarter valued at about $246,000. Jump Financial LLC bought a new stake in shares of Afya in the third quarter valued at about $819,000. Finally, Marshall Wace LLP bought a new stake in shares of Afya in the third quarter valued at about $399,000. 88.02% of the stock is currently owned by institutional investors and hedge funds.
Afya Company Profile
Afya Limited is a Brazilian medical education and digital health company. Its education business offers undergraduate medical degree programs, medical residency preparation, postgraduate courses and continuing education for health professionals. The company also provides digital tools and services for medical students and practicing physicians, including clinical reference, practice-management and learning resources. These offerings support professionals at different stages of their medical careers.
Further Reading
- Five stocks we like better than Afya
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
